MX2016011025A - Composiciones de grapiprant y metodos para usar las mismas. - Google Patents

Composiciones de grapiprant y metodos para usar las mismas.

Info

Publication number
MX2016011025A
MX2016011025A MX2016011025A MX2016011025A MX2016011025A MX 2016011025 A MX2016011025 A MX 2016011025A MX 2016011025 A MX2016011025 A MX 2016011025A MX 2016011025 A MX2016011025 A MX 2016011025A MX 2016011025 A MX2016011025 A MX 2016011025A
Authority
MX
Mexico
Prior art keywords
grapiprant
human animal
compositions
methods
same
Prior art date
Application number
MX2016011025A
Other languages
English (en)
Inventor
Devaraj Gopinath
RAUSCH-DERRA Lesley
NEWBOLD Tamara
Shiraishi Akemi
Original Assignee
Aratana Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54016294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016011025(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aratana Therapeutics Inc filed Critical Aratana Therapeutics Inc
Publication of MX2016011025A publication Critical patent/MX2016011025A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

La presente descripción proporciona un método para el tratamiento del dolor o la inflamación en un animal no humano con necesidad del mismo. El método comprende la administración a un animal no humano de una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de grapiprant. También se proporcionan en la presente composiciones farmacéuticas para el tratamiento del dolor o la inflamación en un animal no humano con necesidad del mismo. Las composiciones farmacéuticas comprenden una cantidad terapéuticamente eficaz de grapiprant y un excipiente, incluyendo saborizantes.
MX2016011025A 2014-03-06 2015-03-05 Composiciones de grapiprant y metodos para usar las mismas. MX2016011025A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461948957P 2014-03-06 2014-03-06
US201462089713P 2014-12-09 2014-12-09
PCT/US2015/019037 WO2015134792A1 (en) 2014-03-06 2015-03-05 Compositions of grapiprant and methods for using the same

Publications (1)

Publication Number Publication Date
MX2016011025A true MX2016011025A (es) 2016-11-29

Family

ID=54016294

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016011025A MX2016011025A (es) 2014-03-06 2015-03-05 Composiciones de grapiprant y metodos para usar las mismas.
MX2022014763A MX2022014763A (es) 2014-03-06 2016-08-24 Composiciones de grapiprant y metodos para usar las mismas.
MX2020001428A MX2020001428A (es) 2014-03-06 2016-08-24 Composiciones de grapiprant y metodos para usar las mismas.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022014763A MX2022014763A (es) 2014-03-06 2016-08-24 Composiciones de grapiprant y metodos para usar las mismas.
MX2020001428A MX2020001428A (es) 2014-03-06 2016-08-24 Composiciones de grapiprant y metodos para usar las mismas.

Country Status (15)

Country Link
US (2) US11369621B2 (es)
EP (1) EP3113774B1 (es)
JP (1) JP6419857B2 (es)
KR (1) KR102270323B1 (es)
CN (2) CN112370450A (es)
AU (1) AU2015227059B2 (es)
CA (1) CA2941008C (es)
DK (1) DK3113774T3 (es)
ES (1) ES2907285T3 (es)
MX (3) MX2016011025A (es)
PL (1) PL3113774T3 (es)
PT (1) PT3113774T (es)
RU (1) RU2679631C2 (es)
TW (2) TWI664969B (es)
WO (1) WO2015134792A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220096501A1 (en) * 2014-12-09 2022-03-31 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
WO2020014465A1 (en) * 2018-07-11 2020-01-16 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
EP3856177A4 (en) * 2018-09-27 2022-06-29 Arrys Therapeutics, Inc. Grapiprant unit dosage forms
WO2021205367A1 (en) * 2020-04-08 2021-10-14 Askat Inc. Use of ep4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2479A1 (fr) * 1997-05-05 2003-02-01 Pfizer Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.
JP2003506404A (ja) * 1999-08-10 2003-02-18 グラクソ グループ リミテッド 治療、とりわけ神経障害性疼痛および結腸癌の治療におけるｅｐ４受容体リガンドの使用
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
US20050059742A1 (en) * 2001-10-31 2005-03-17 Jabbour Henry Nicolas Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorphagia
CA2481535C (en) 2002-04-12 2010-08-17 Pfizer Inc. Use of ep4 receptor ligands in the treatment of il-6 involved diseases
MXPA06012172A (es) * 2004-04-20 2007-01-17 Pfizer Prod Inc Combinaciones que comprenden ligandos alfa-2-delta y antagonistas del receptor ep4.
CA2600510C (en) 2005-03-11 2010-11-02 Pfizer Inc. Crystal forms of an imidazole derivative
US7968578B2 (en) 2006-04-24 2011-06-28 Merck Frosst Canada Ltd. Indole amide derivatives as EP4 receptor antagonists
US20080242713A1 (en) * 2007-03-28 2008-10-02 Bayer Schering Pharma Aktiengesellschaft Novel 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases
CN107693518A (zh) 2010-02-22 2018-02-16 株式会社ＡｓｋＡｔ Ep‑4受体拮抗剂在治疗il‑23介导疾病中的用途
WO2011124525A1 (de) * 2010-04-08 2011-10-13 Boehringer Ingelheim International Gmbh Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
US9173944B2 (en) 2010-10-12 2015-11-03 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
AU2012225459A1 (en) * 2011-03-08 2013-10-10 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
KR20190015614A (ko) 2011-05-18 2019-02-13 라퀄리아 파마 인코포레이티드 4-｛[4-(｛[4-(2,2,2-트리플루오로에톡시)-1,2-벤즈이속사졸-3-일]옥시｝메틸)피페리딘-1-일]메틸｝-테트라히드로-2h-피란-4-카르복실산의 다형
ITBO20110461A1 (it) * 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
BR112015023663A2 (pt) 2013-03-19 2020-10-20 Askat Inc. uso de um composto com atividade antagonística de ep4 ou um sal farmaceuticamente aceitável deste, uso de um composto da fórmula (i), (ii), (iii), (iv), (va) ou (vb) ou um sal farmaceuticamente aceitável deste, composição farmacêutica para o tratamento de doença de cartilagem, método para o tratamento de doenças de cartilagem em um indivíduo animal, incluindo um indivíduo mamífero e composto da fórmula (i), (ii),(iii), (iv), (va) ou (vb) ou um sal farmaceuticamente aceitável deste
CN107400132A (zh) 2014-03-06 2017-11-28 阿莱塔纳治疗学股份有限公司 Grapiprant的结晶形式

Also Published As

Publication number Publication date
US20150250773A1 (en) 2015-09-10
TW201815393A (zh) 2018-05-01
CA2941008A1 (en) 2015-09-11
ES2907285T3 (es) 2022-04-22
EP3113774A1 (en) 2017-01-11
RU2019102384A (ru) 2019-03-04
AU2015227059B2 (en) 2018-11-15
WO2015134792A1 (en) 2015-09-11
KR20160129887A (ko) 2016-11-09
MX2020001428A (es) 2020-03-20
MX2022014763A (es) 2023-01-11
RU2019102384A3 (es) 2022-03-31
CA2941008C (en) 2022-07-26
KR102270323B1 (ko) 2021-06-29
RU2679631C2 (ru) 2019-02-12
AU2015227059A1 (en) 2016-09-22
RU2016137926A (ru) 2018-04-09
EP3113774B1 (en) 2022-01-26
JP6419857B2 (ja) 2018-11-07
JP2017507190A (ja) 2017-03-16
EP3113774A4 (en) 2017-10-25
PT3113774T (pt) 2022-02-28
CN112370450A (zh) 2021-02-19
TW201603812A (zh) 2016-02-01
DK3113774T3 (da) 2022-03-07
TWI664969B (zh) 2019-07-11
NZ761827A (en) 2021-03-26
US20160317559A1 (en) 2016-11-03
NZ724007A (en) 2021-02-26
TWI708606B (zh) 2020-11-01
US11369621B2 (en) 2022-06-28
PL3113774T3 (pl) 2022-06-13
CN105939713A (zh) 2016-09-14

Similar Documents

Publication Publication Date Title
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
PH12016501790B1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12016501788B1 (en) Pharmaceutical compositions of therapeutically active compounds
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MY188139A (en) Sodium channel modulators for the treatment of pain
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MX2018005628A (es) Tratamientos de grasa acumulada con acido desoxicolico y sales del mismo.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2017011018A (es) Inhibicion de la actividad de olig2.
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
PH12016500910A1 (en) Long-acting ketoprofen compositions
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
IN2013MU03428A (es)
NZ725354A (en) Transdermal formulations of pergolide and uses thereof
PH12020500472A1 (en) Autotaxin inhibitor compounds
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
AR099681A1 (es) Composiciones de grapiprant y métodos para su utilización
IN2013MU03429A (es)
IN2014DE00822A (es)

Legal Events

Date Code Title Description
FG Grant or registration